IN THE CLAIMS:

1. (Currently Amended): A compound of the formula

$$R_2$$
 R_1 I

where R₁ is of the formulae

$$-N$$
 $N-R_3$, $N-R_3$, or

II

 R_2 is $-R_4$, $-O-R_4$, $-O-S(O)_2-R_4$, $-NR_4R_5$, $R_4-(CH_2)_b-NH(C=X)-(CH_2)_c-$,

R₄-(CH₂)_b-O(C=O)NH-(CH₂)_c-(C=O)NH-, R₄-(C=O)NH-(C=O)NH-,

 $-(CH_2)_b-NH(C=X)-(CH_2)_c-R_4$, $R_4-(CH_2)_b-O(C=O)-(CH_2)_c-$, $-(CH_2)_b-O(C=O)-(CH_2)_c-R_4$,

-NH(C=X)NH-R₄, R₄-O(C=O)O-, -O(C=O)NH-R₄, R₄-O(C=O)NH-,

 $-(CH_2)_b-(C=O)-(CH_2)_c-R_4$, $-NH-S(O)_2-R_4$, $-C(OH)R_4R_5$, $-CH(OH)-R_4$, $-(C=O)-NR_4R_5$, -CN,

-NO₂, substituted C_1 to C_6 alkyl, substituted or unsubstituted C_4 C_2 to C_6 alkenyl, or substituted or unsubstituted C_4 C_2 to C_6 alkynyl, said substituted moieties substituted with a moiety of the formulae -R₄, -R₄R₅, -O-R₄, or -S(O)_d-R₄;

 R_3 is hydrogen, $CH_3OCH_2CH_2$, C_1 to C_6 alkyl, C_1 to C_6 alkylaryl, or aryl; R_4 and R_5 are each independently

$$R_{7}$$
 R_{1}
 R_{1}

hydrogen, $-CF_3$, C_1 to C_6 alkyl, C_1 to C_6 alkylaryl, with the proviso that when R_2 is $-R_4$ or $-OR_4$, R_4 is not hydrogen or C_1 to C_6 alkyl;

 $R_{6}, R_{7}, R_{8}, R_{9}, R_{10}, R_{11}, R_{12}, R_{13}, R_{14}, R_{15}, R_{16}, R_{17}, \text{ and } R_{18} \text{ are each independently H,} \\ \text{halogen, -CF}_{3}, \text{-(C=O)} \\ R_{20}, \text{-CN, -OR}_{20}, \text{-NR}_{20} \\ R_{21}, \text{-NR}_{20} \\ \text{SO}_{2} \\ R_{22}, \\ \text{-NR}_{20} \\ \text{-NR}_{2$

 $-N=C-N(CH_3)_2$, $-N_{20}CO_2R_{22}$, $-S(O)_eR_{20}$, $-SO_2NR_{20}R_{21}$, $-NO_2$, aryl, C_1 to C_6 alkylaryl,

-(C=O)OR₂₀,-(C=O)NR₂₀R₂₁, C₁ to C₆ alkyl, C_4 C_2 to C₆ alkenyl, and C_4 C_2 to C₆ alkynyl;

R₆ and R₇, R₇ and R₈, R₈ and R₉, R₉ and R₁₀, R₁₁ and R₁₂, R₁₂ and R₁₃, R₁₃ and R₁₄, R₁₅ and R₁₆, R₁₆ and R₁₇, and R₁₇ and R₁₈ may be taken together with the ring atoms to which they are attached to form a five-to-seven-membered alkyl ring, a six-membered aryl ring, a five to

seven membered heteroalkyl ring having one heteroatom of N, O, or S, or a five-to sixmembered heteroaryl ring have 1 or 2 heteroatoms of N, O, or S;

 R_{19} is hydrogen or C_1 to C_3 alkyl;

 R_{20} and R_{21} are each independently hydrogen, C_1 to C_6 alkyl, aryl, or C_1 to C_6 alkylaryl, or may be taken together to form a C_4 to C_7 alkyl ring;

 R_{22} is C_1 to C_6 alkyl, aryl, or C_1 to C_6 alkylaryl;

A, B, D, E, and F are each independently C or N;

G, I, J, and K are each independently C, N, O, S, or (C=O), with the proviso that there is at most one of O, (C=O), or S per ring;

L and Z are each independently C or N;

M is C, N, or (C-O)(C-240);

X is O or S;

a is 0, 1 or 2;

e is 0, 1 or 2;

d is 0, 1, or 2;

b and c are each independently 0, 1, 2, 3, 4, 5, or 6, with b+c being at most 6;

a broken line indicates the presence optionally of a double bond and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C_1 to C_4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1 to C_4 alkoxy, and pharmaceutically acceptable salts thereof.

2. (Currently Amended): The compound of claim 1, wherein R₁ is formula II; R₂ is -R₄, -OR₄,

R₄-(CH₂)_b-NH(C=X)-(CH₂)_c-, or -(CH₂)_b-NH(C=O)-(CH₂)_c-R₄; R₃ is hydrogen or C₁ to C₆ alkyl; R₄ is formula XV or formula XVII; A, B, D, E, and F are each independently C or N; R₆, R₇, R₈, R₉, R₁₀, R₁₅, R₁₆, R₁₇, R₁₈, and R₁₉ are each independently hydrogen, halogen, -CN, or -OR₂₀; and R₂₀ is C₁ to C₆ alkyl.

- 3. (Withdrawn): The compound of claim 1, wherein R_1 is formula III; R_2 is $-R_4$, $-OR_4$, R_4 - $(CH_2)_b$ -NH(C=X)- $(CH_2)_c$ -, or $-(CH_2)_b$ -NH(C=O)- $(CH_2)_c$ - R_4 ; R_4 is formula XV or formula XVII; R_3 is hydrogen or C_1 to C_6 alkyl; A, B, D, E, and F are each independently C or N; R_6 , R_7 , R_8 , R_9 , R_{10} , R_{15} , R_{16} , R_{17} , R_{18} , and R_{19} are each independently hydrogen, halogen, -CN, or $-OR_{20}$; and R_{20} is C_1 to C_6 alkyl.
- 4. (Withdrawn): The compound of claim 1, wherein R₁ is

 R_2 is $-R_4$, $-OR_4$, R_4 - $(CH_2)_b$ -NH(C=X)- $(CH_2)_c$ -, or $-(CH_2)_b$ -NH(C=O)- $(CH_2)_c$ - R_4 ; R_3 is hydrogen or C_1 to C_6 alkyl; R_4 is formula XV or formula XVII; A, B, D, E, and F are each independently C or N; R_6 , R_7 , R_8 , R_9 , R_{10} , R_{15} , R_{16} , R_{17} , R_{18} , and R_{19} are each independently hydrogen, halogen, -CN, or $-OR_{20}$; and R_{20} is C_1 to C_6 alkyl.

5. (Currently Amended): The compound of claim 1, wherein R_1 -is formula II, formula III, or formula IV; R_2 is $-R_4$; R_3 is hydrogen or C_1 to C_6 alkyl; R_4 is formula XVII; G, G, G, and G are

each independently C, N, or O; L is C; R_{11} , R_{12} , R_{13} , and R_{14} are each independently hydrogen, C_1 to C_6 alkylaryl.

- 6. (Original): The compound of claim 1, said compound being selected from:
 - 7-(Imidazolo[4,5-b]pyridin-1-yl)-1-(I-methylpyrrolidin-3-yl)naphthalene;
 - 7-(4-Chlorobenzamido)-1-(pyrrolidin-2-(R)-ylmethyl)naphthalene;
 - 2-[8-(4-Methylpiperazin-1-yl)naphthalen-2-yloxy]nicotinonitrile;
 - 1-(4-Methylpiperazin-1-yl)-7-pyrimidin-5-yl)naphthalene;
 - 7-(5-Cyanopyridin-3-yl)-1-(4-methylpiperazin-1-yl)naphthalene;
 - 1-(Piperazin-1-yl)-7-(pyrimidin-5-yl)naphthalene;
 - 7-(4-Chlorobenzamido-1-(4-methylpiperazin-1-yl)naphthalene;
 - 7-(3-Methoxyphenyl)1-(4-methylpiperazin-1-yl)naphthalene;
 - 7-(Imidazolo[4,5-b]pyridin-1-yl)-1-(4-methylpiperazin-1-yl)naphthalene;
 - 8-(4-Methylpiperazin-1-yl)naphthalene-2-carboxylic acid 4-chlorobenzylamide;
 - 7-(4-Methoxyphenyl)-1-(4-methylpiperazin-1-yl)-naphthalene;
 - 7-Pyrimidin-2-yloxy-1-(4-methylpiperazin-1-yl)naphthalene;
 - 7-(Benzimidazol-1-yl)-1-(4-methylpiperazin-1-yl)naphthalene; and
 - 8-(1-Methylpiperidin-4-yl)naphthalene-2-carboxylic acid 4-chlorobenzylamide.
- 7. (Original): A pharmaceutical composition for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, Alzheimer's disease, and chronic paroxysmal hemicrania and headache


associated with vascular disorders comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.

- 8. (Original): A pharmaceutical composition for treating disorders arising from deficient serotonergic neurotransmission comprising an amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.
- 9. (Original): A method for treating a condition selected from hypertension, depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, Alzheimer's disease, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such condition.
- 10. (Original): A method for treating disorders arising from deficient serotonergic neurotransmission comprising administering to a mammal requiring such treatment an amount of a compound according to claim 1 effective in treating such condition.
- 11. (Currently Amended): A compound of the formula

$$R_2$$
 R_1 I

where R₁ is of the formulae

$$\begin{array}{c|c}
\hline
-N & N-R_3, & N-R_3, & or \\
\hline
III & IIII
\end{array}$$



 R_2 is $(Methyl)_3Sn$ - or $(Butyl)_3Sn$ -; R_3 is hydrogen, C_1 to C_6 alkyl, C_1 to C_6 alkylaryl, or aryl; a is 0, 1, or 2; and a broken line indicates the presence optionally of a double bond and the above aryl groups and the aryl moieties of the above alkylaryl groups are independently

selected from phenyl and substituted phenyl, wherein said substituted phenyl may be substituted with one to three groups selected from C_1 to C_4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, and C_1 to C_4 alkoxy.